2 active not recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 2 |
Follow Recurrent Melanoma: new trials by email Literature Review of Recurrent Melanoma trials Research Report on Recurrent Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma Biospecimen Collection, Computed Tomography, Dabrafenib Mesylate - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 267 | 2015-09-08 | 2026-10-26 |
| Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Ipilimumab, Quality-of-Life Assessment, Recombinant Interferon Alfa-2b - Melanoma of Unknown Primary, Recurrent Melanoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 1673 | 2011-06-17 | 2026-10-22 |
Melanoma (2)
Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Nerve Tissue (2) · Neuroectodermal Tumors (2) · Neuroendocrine Tumors (2) · Nevi and Melanomas (2) · Skin Diseases (2) · Skin Neoplasms (2) · Skin and Connective Tissue Diseases (2)
CTLA-4 Antigen (2) · Ipilimumab (2) · Interferon alpha-2 (1) · Introns (1) · Nivolumab (1) · Specimen Handling (1) · dabrafenib (1) · trametinib (1)
National Cancer Institute (NCI) (2)
United States (2) · Canada (1)
Ahmad Tarhini (1) · Michael B Atkins (1)
PMID 25649350, PMID 29784747, PMID 35659704, PMID 36029412, PMID 36166727
U10CA180820 (2), P50CA121973 (1), U10CA021115 (1), U24CA196172 (1)